PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

The review of urologie literature from November, 2001 to October, 2002
Article published in Urologia Polska 2003/56/1.

authors

Andrzej Borkowski, Tomasz Borkowski

references

  1. 1. Hofer Ch. Kubler H. Hartung R i wsp:Diagnosis and monitoring ofurologkal tumors using positron emission tomography. Eur Urol 2001; 40: 481-487.
  2. 2. Soria J-Ch. Mortal I„ Durdux C i wsp: Vie molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol 2002; 167:352-356.
  3. 3. Holmang S. Johansson ST.. Stage Ta-Tl cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002; 167:1634-1637.
  4. 4. Yossepowitch O. Dalbagni G:Transitional cell carcinoma of the bladder in young adults; presentation, naturall history and outcome. J Urol 2002:168:61-66.
  5. 5. Martinez - Pineiro JA, Flores N. Isoma S i wsp; Long-term follow-up of
  6. a randomized prospective trial comparing a standard 81 mg dose of intravesical bacillle Calmette - Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU International 2002:89: 671-680.
  7. 6. Griffiths TRL, Charlton M. Neal DE i wsp; Treatment of carcinoma in situ with intravesical Bacillus Calmette-Guerin without maintenance. J Urol 2002; 167; 2408-2412.
  8. 7. Morales A, Chin JL. Ramsey EW:Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001; 166: 1633-163S.
  9. 8. Millikan R. Dinney C, Swanson D i wsp: Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy both preoperative and postoperative M-VAC. J Clin Oncol 2001:19:4005-4013.
  10. 9. Bajorin DF i wsp: Plenary debate of randomized phase ill trial of neoadjuvant MVACplus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol 2001:19: 17-20.
  11. 10. Vogelzang NT: Neoadj uvant MVAC: The long and winding road is getting shorter and stmighter.} Clin Onco\\\\ 2001:19:4003-4004.
  12. 11. Sternberg CN. Parmar MSB: Neoadjuvant chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol 2001;19:21-26.
  13. 12. Ilerrr IIW Bochner BH. Dalbagni G i wsp: Impact of the number of lymph nnodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 2002; 167:1295-1298.
  14. 13. Chang SS, Cole E, Smith Jr. A i wsp:Pathological findings of gynecologic organs obtained at female radical cystectomy.] Urol 2002; 168: 147-149.
  15. 14. Hock LVI, Lynch J. Balaji KC:Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis ofsurveillen-ce. epidemiology and end results program data. J Urol 2002; 167:57-60.
  16. 15. Pantuck AJ. Zismarj A. Belldegrun AS: Tlie changing natural history of renal cell carcinoma. J Urol 2001:166:1611-1623.
  17. 16. Terada N, Ichioka K. Matsuta Y i wsp: The natural history of simple re-nalcysls. J Urol 2002:167: 21-23.
  18. 17. Zhang JQ. Fielding JL, Zou KTI:Etiology of spontaneous perirenal hemorrhage. A meta-analysis. ]llm\\\\ 2002; 167:1593-1596.
  19. 18. Koga S, Tsuda S, Nishikkido M: The diagnostic value of bone stan in patients with rend cell carcinoma. | Urol 2001; 166: 2126-2128.
  20. 19. De Baere Th, Kouch V. Smayra T i wsp: Radio frequency ablation of renal cell carcinoma: preliminary clinical experience. J Urol 2002; 167: 1961-1964.
  21. 20. Pavlovich ChP. McClellan M. Walther M i wsp: Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol 2002:167: 10-15.
  22. 21. Rendon RA. Kaehura JR. Sweet JM i wsp: The uncertainty ofradiofre-quency treatement of renal cell carcinoma:findings at immediate and delayed nephrectomy.] Vlml 2002. 167:1587-1592.
  23. 22. Sutherland SE. Resnik Ml. Madennan T i wsp: Does the. size of the surgical margin in partial nephrectomy for renal cancer really matter? J Urol 2002;167:61-64,
  24. 23. Piper NY. Bishof JT, Magee CII i wsp: is a 1-cin margin necessary during nephron-SjMring surgery for renal cell carcinoma? Urology 2001; 58:849-852.
  25. 24. Hatano T. Sugaya K, Morozumi M i wsp: Partid nephrectomy using a vascular sealing system. JUrol 2002:167: 232-233.
  26. 2 5. Me jaen A. Vogt B, Cazin S. i wsp:Nephron sparing surgery for rencd cell carcinoma using selective renal parenchymal clamping. J Urol 2002; 167:234-235.
  27. 26. Salvador-Bayarri J. Rodriguez-Villamil L. ImperaloreV i wsp:Bladder neoplasms after nephroureterectomy; does the surgery of the lower ureter. transurethral resection, oroj\\\'en surgery, influence the evolution? Eur Urol 2002:41:30-33,
  28. 27. Heidenreich A, Weisshach L. IIolll W i wsp: Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001; 166:2161-2165.
  29. 28. Elert A, Olbert P. Hegele A i wsp:Accuracy of frozen section examination oftesticidar tumors of uncertain origin. Eur Urol 2002; 41:290-293.
  30. 29. Shahidi M, Norman AR, Dearnaley UP i wsp: late recurrence, in 1263 men with testicular germ cell tumors.Midtivariate analysis of risk factors and implications for management. Cancer 2002: 95: 520-530.
  31. 30. Brooks TD, Metier EJ, Chan DW i wsp:Plasma selenium lew! before diagnosis and the risk of prostate cancer development. J Urol 2001:166:2034-2038
  32. 31. Giovannucci E. Rimm EB, Liu Y ii wsp: A prospective study of tomato products, lycopene and prostate cancer risk. J Natl Cancer Inst 2002; 94:391-398.
  33. 32. Saxe GA. Hcbert JR. Carmody JF i wsp: Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer?] Urol 2001: 166: 2202-2207.
  34. 33. Morales A: Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-120.
  35. 34. Marks LS, UiPaola RS, Nelson P i wsp: PC-spes: herbal formulation for prostate cancer. Urology 2002; 60:369-377.
  36. 35. Wehbi NIC. Dugger AL. Bonner RB i wsp: Pan-cadherin as a high llevel phenolypic biomarker for prostate cancer J Urol 2002: 167: 2215-2221.
  37. 36. Francini G, Perrioli R, Gonnelli S i wsp: Urinary caelum excretion in the monitoring of bone metastases from prostatic carcinoma. Cancer 2001:92:1468-1474.
  38. 17. Moul Jl): Editorial: Prostate biopsy quantitative histology as a staging and prognostic factor. JUrol 2002:167:526-527.
  39. 38. Freedland SJ. Csalhy GS. Dorey F i wsp: Percent prostate tissue with cancer is more predictive of bkxhemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol 2002; 167: 516-520.
  40. 59. Veltri RV. Miller MC, Mangold LA i wsp: Prediction of pathological stage in patients with clinical stage Tic prostate cancer: the new challenge. JUrol 2002; 168:100-104.
  41. 40. D\\\'Amico AV Predicting prostate-specific antigen recwrece established: now. who will survive. Editorial. J Clin Oncol 2002: 20:3188-3190.
  42. 41. Holmerg L, Bill-Axclson A, Helgesen F i wsp: A randomized traial comparing radicalprostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002: 347: 781-789.
  43. 42. Steineck G. Helgesen P. Adoflsson J i wsp: Quality of life after radical prostatectomy or watchful waiting.Engl J Med 2002; 347: 790-796.
  44. 43. Carter BH. Walsh PC, Landis P i wsp:Expectant management of non palpable prostate cancer with curative intent:preliminary results. J Urol 2002:167:1231-1234.
  45. 44. Epstein JT, Walsh PC. Carter HB:Dedifferenliation of prostate cancer grade with time in men followed expectantly for stage Tic disease. J Urol 2001; 166:1688-1691.
  46. 45. Schmid II-F, Adolfsson J, Aus G:Active monitoring (deffcredtreatement or watchful waiting) in the. treatment of prostate cancer. Eur Urol 2001; 40:488-494.
  47. 46. Lepor II, Nieder AM, Ferrandino MN:Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 7000 cases. J Urol 2001; 166:1729-1733.
  48. 47. Burkhard FC, Bader P. Schneider E i wsp: Reliability of preoperative values to determine the needfor lymphadenectomy inpatients with prostate cancer and meticulous lymph node dissection. Eur Urol 2002: 42: 84-92.
  49. 48. Bader P. Burkhard FC. Markwalder R i wsp: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168:514-518.
  50. 49. Holla M, Collelte L. Blank L i wsp:Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase 111 randomized trial. The Lancet 2002; 360:103-108.
  51. 50. Bagley CliM. Lane RE Blasko JC i wsp: Adjuvant Chemohormona! therapy of high risk prostate carcinoma. Cancer 2002; 94: 2728-2732,
  52. 51. Dcger S, Boehmer D, Turk I i wsp:Interstitial hyperthermia using self--regidating thermoseeds combined with conformal radiation therapy. Eur Urol 2002; 42:147-153.
  53. 52. Nathan TR. Whilelaw DE. Chang SC i wsp: Pholodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol 2002; 168:1427-1432.
  54. 53, Rembielak A. Slosarek K: Modulacja aktywności wiązki w leczeniu raka prostaty. Nowotwory 2002; 52:1.50-153. 51.
  55. 54. Deger S, Boehmer D, Turk I i wsp:High dose brachyterapii of localized prostate cancer. Eur Urol 2002; 41:420-426.
  56. 55. Iversen P. Tammela TLJ, Vaage S i wsp: A randomised comparison ofBi-calutamide (Casodex) 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-melastatic prostate cancer. First report from Scandinavian Prostate Cancer Croup Study Nr 6. Eur Urol 2002: 42: 204-211.
  57. 56. Samson DJ. Seidenfeld J. Schmitt B i wsp: Systematic review and meta--analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002: 95: 361-376.
  58. 57. Potosky Al, Knopf K. Clegg 1.X i wsp: Quality of life outcomes after primary androgen deprivation therapy:results from the prostate cancer outcomes study. J Clin Oncol 2001; 19:.3750-3757.
  59. 58. Scherr D, Pitts WR. Vaughan ED jr:Diethylstilbcstrol revisited:androgen deprivation, osteoporosis and prostate cancer J Urol 2002: 167: .535-538.
  60. 59. Wright EJ, Fang J. Meller EJ i wsp:Prostate specific antigen predicts the long-term risk of prostate enlargement results from the Baltimore longitudinal study of aging. J Urol 2002; 167:2484-2488.
  61. 60. Roehrborn CG, McConnell JD, Saltzman B i wsp: Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002:42:1-6.
  62. 61. McConnell p for MTOPS Steering Committee: The long term effects of medical therapy on the progression ofBPH: results of MTOPS trial. J Urol 2002; 167. suppl. nr 4. abstr, 1042:265.
  63. 62. Roehborn CG, Boyle P. Nickel JC i wsp: Efficacy and safety of a dual inhibitor of 5-dpha-reductase types I and 2 (Dutasteride) in men with benign prostatic hyperplasia. Urology 2002:60:434-441.
  64. 63. Debruyne F. Koch G, Boyle P i wsp:Comparison of a phylotherapeutic agent (Permixon) witlt an alpha blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002: 41:497-507.
  65. 64. Porrou D, Jallous H, Cavalli V i wsp: Prognostic value of a combination oflPSS. flow rate and residual wine volume compared to pressure-flow studies in the preoperative evolution of symptomatic KPH. Fur Urol 2002:41:246-249.
  66. 65. Wadie BS. El-Husseiny EE, Gomha MA:The relationship of detrusor instability and symptoms with objective parameters used for diagnosing bladder outlet obstruction: aprospective study. J Urol 2002; 168:132-134.
  67. 66. Thalaman GN, Matlei A. Treulhardl C i wsp: Transurethral microwave therapy in 2000patients with a minimum followup of 2 years: urody-namic and clinical results. J Urol 2002:167:2496-2 501.
  68. 67. Savoca G. De Stefani S, Gattuceio I i wsp: Percuteneous ethanol injection of the prostate as minimally invasive treatment for benign prostatic hyperplasia: preliminary report.Eur Urol 2001; 40; 504-508.
  69. 68. Holmes M. Cox J. Stewart J i wsp:Thick vs thin loop transurethral resection of the prostate: a double-blind prospective trial of early morbidity. BJU International 2002:89:197-201.
  70. 69. Beelz R. Mannnhardt W. Fisch M i wsp: Long-term followup of 158 young adidts surgically treated for vesicoureteral reflux in childhood: the ongoing risk of urinary tract infections. | Urol 2002:168: 704-707.
  71. 70. Kreder K, Mayne C. Jonas U:Long-term safety, tolembility and efficacy oj extended-release Toiterodine in the treatment of overactive bladder. Eur Urol 2002: 41: 588-59.5.
  72. 71. Rovner KS. VVein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002:41: 6-14.
  73. 72. Matfiassson A. Abrams R Van Kerrebroeck P i wsp: Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU International 2002: 89: 855-862.
  74. 73. Hussein Mohamed EEH: The role of pelvic traction in management of primary monosymptomatic nocturnal enuresis. BPII International 2002: 89:416-419.
  75. 74. Pecker R. Fall M: Toward a precise definition of interstitial cystitis:further evidence of differences in classic and nonulcer disease. J Urol 2002:167: 2470-2472.
  76. 75. Weiss JM: PeM floor myofascial trigger points: manual therapy for interstitial cystitis an the urgency-frequency syndrome. J Urol 2001:166: 2226-2231.
  77. 76. Wammack R, Reinzi M. Seitz T i wsp:Efficacy of oral Doxepin and Pi-roxicam treatment for interstitial cystitis. Eur Urol 2002: 41: 596-601.
  78. 77. De Seze M, Petit H, Gallien Ph i wsp: Botulinum A toxin and detrusor sphincter dyssynergia: a double, blind Lidocaine-controlled study in I 3 patients with spinal cord disease. Eur Urol 2002; 42: 56-62.
  79. 78. Gordon D. GoRS, Pauzner D i wsp:Combined genitourinary prolapse repair and prophylactic tension-free vaginal tape in women with severe prolapse and occult, stress urinary incontinence. Urology 2001: 58: 547-550.
  80. 79. Champetier 1), Ruffion A, Lopez J-G. i wsp: Ajustement differe de la tension de materiel prothetique sous-urelhial (TVT) apres cure chirurgicale ^incontinence urinaire d\\\' effort de lafemine. Progres en Urologie 2001; 11:1314-1319.
  81. 80. Manila M. Bhaumik J. Davies AE:Sexual function after using tension--free vaginal tape for the surgical treatment of genuine stress incontinence. BJU International 2002:90:540-543.
  82. 81. Gurakiiek ML Miller E, Ton KI. i wsp: Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and ureth-ralatrophy. j Urol 2002:167:2075-2079.
  83. 82. Hsu TIIS. Rackley RR, Abdelmalak JB i wsp: Novel technique for repair of postirradiation vesicovaginal fistula and augmentation Heocystoplasty. Urology 2002; 59: 597-599.
  84. 83. fncrocci L, Slob K: Incidence, etiology, and therapy for erectile dysfunction after external beam radiotherapy for prostatę, cancer. Urology 2002: 60: 1-7.
  85. 84. Meng VM. Koppie TM, Uuh Q-Y i wsp:Novel method of assessing surgical margin status in laparoscopic specimens. Urology 2001: 58: 677-682.
  86. 8 5. Turk I, Davis JW, Deger S i wsp:Laparoskopische radikale Zysteklomie
  87. mit intrakorporaler Anlage einer kontinennten Harnableilung. Llrologe [Al 2002: 41:107-112.
  88. 86. Gill IS, Desai MM, Kaouk |H i wsp:Laparoscopic partial nephrectomy for renal tumor: duplicating open surgical techniques. J Urol 2002: 167: 469-476.
  89. 87. Sung GT, Gill IS: Robotic laparoscopic surgery: a comparison of the da Vinci and\\\'/eus systems. Urology 2001: 58: 893-898.
  90. 88. Hoznek A, Zakki SK. Samadi DB i wsp:Robotic assisted kidney transplantation:an initial experience. J Urol 2002:167:1604-1606.
  91. 89. Shalii M, Murphy DM. Donovan MG i wsp: Is mechanical bowel preparation necessary in patients undergoing cystectomy and urinary diversion. BJO International 2002 89: 879-881.
  92. 90. Jonsson 0. Olol\\\'sson G, Lindliolm H i wsp: Long-time experience with the Kock Had reservoir for continent urinary diversion. Kur Urol 2001: 40: 632-640.
  93. 91. Matlaga BR, Assimos DG: Changing indications of open stone surgery.
  94. Urology 2002; 59: 490-494.
  95. 92. Shoma AM, Kraky I, El-Kenawy MR i wsp: Percutaneous nephrolithotomy in the supine position: technical aspects and functional outcome compared with the. prone technique. Urology 2002; 60:388-392,
  96. 93.1 lollenbeck BK. Schuster TG, Faerber GJ i wsp: Flexible urethroscopy in
  97. conjunction with in situ lithotripsy for lower pole calculi. Urology 2001:58:859-863.
  98. 94. El-Anany FG. Ilammouda 1IM. Maghraby HA i wsp: Retrograde ure-teropyeloscopic hdlmium laser lithotripsy for large renal calculi. I3JI: International 2001:88: 850-853.
  99. 95. Miller SD, Ng ChS, Slreem Sli i wsp:Laparoscopic management ofcali-ceal diverticular caladi.] Urol 2002:167:1248-1252.
  100. 96. Auge BK. Lallas CD. Pietrow PK i wsp: In vitro comparison of standard tdtrasound and pneumatic lithotrites with a new combination intracorpo-real lithotripsy device. Urology 2002:60:28-32.
  101. 97. Watterson JD. Girvan AR, Bciko DT i wsp: Ureteroscopy and holiniwn: Yag laser lithotripsy: an emerging definitive management strategy for symptomatic ureteral calculi in pregnancy. Crology 2002: 60: 383-387.
  102. 98. Yohannes P, Smith AD: The endourological management of complications associated with horseshoe kidney. J Urol 2002; 168: 5-8.
  103. 99. Laven BA, O\\\'Connor R.C, Steinberg GD i wsp: Long-term results of antegrade endoureterotomy using the holiniwn laser in patients with urele-rointestinai strictures. Urology 2001: 58: 924-929.
  104. 100. Daneshmand S, Huffman JL:Endoscopic management of renal heman-gioma. J Urol 2002:167:488-489.